CDK4 and melanoma: However, it has been demonstrated that CDK4/6 activity drives ICI resistance in RB competent immune cold melanoma tumor but when mouse models of these resistant melanoma tumors are treated first with ICI followed by CDK4/6 inhibition plus ICI, the resistance program is overcome and tumor growth is suppressed, demonstrating that order of delivery of the therapy is important.